Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) COO Tina Marriott sold 3,000 shares of the business's stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $7.67, for a total transaction of $23,010.00. Following the completion of the sale, the chief operating officer now owns 543,231 shares in the company, valued at $4,166,581.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Tina Marriott also recently made the following trade(s):
- On Thursday, March 21st, Tina Marriott sold 8,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.75, for a total transaction of $86,000.00.
- On Thursday, February 22nd, Tina Marriott sold 8,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $14.89, for a total transaction of $119,120.00.
Recursion Pharmaceuticals Trading Up 1.0 %
Shares of RXRX opened at $8.20 on Tuesday. The business's 50-day moving average price is $10.27 and its 200 day moving average price is $9.16. The stock has a market capitalization of $1.92 billion, a P/E ratio of -5.29 and a beta of 0.76. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.54 and a 1-year high of $16.75.
Dividend-like income from non-dividend stocks
From Unstoppable Prosperity | Ad
This coming Wednesday @ 7 PM EST you're going to discover…
How to find safe value in the stocks you already own with simple Cash Flow Trade Strategies.
Click here to register for free.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The company had revenue of $10.89 million for the quarter, compared to analysts' expectations of $12.37 million. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of RXRX. ARK Investment Management LLC grew its stake in Recursion Pharmaceuticals by 200.4% during the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company's stock valued at $203,651,000 after acquiring an additional 13,777,689 shares in the last quarter. Mubadala Investment Co PJSC purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $128,041,000. FMR LLC grew its stake in Recursion Pharmaceuticals by 134.4% during the 3rd quarter. FMR LLC now owns 10,689,532 shares of the company's stock valued at $81,775,000 after acquiring an additional 6,129,935 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in Recursion Pharmaceuticals by 161.2% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company's stock valued at $90,749,000 after acquiring an additional 5,680,656 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. grew its stake in Recursion Pharmaceuticals by 161.2% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 9,203,780 shares of the company's stock valued at $90,565,000 after acquiring an additional 5,680,656 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have commented on RXRX. KeyCorp boosted their price target on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a research report on Monday, March 4th. Needham & Company LLC reissued a "buy" rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Finally, TD Cowen began coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a "market perform" rating on the stock. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and an average price target of $12.75.
Check Out Our Latest Stock Report on Recursion Pharmaceuticals
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
